{"id":2666,"date":"2014-12-19T21:43:00","date_gmt":"2014-12-19T21:43:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2666"},"modified":"2025-01-16T15:41:10","modified_gmt":"2025-01-16T15:41:10","slug":"improved-treatment-on-disease-burden-of-chronic-hepatitis-c-in-new-zealand","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/improved-treatment-on-disease-burden-of-chronic-hepatitis-c-in-new-zealand\/","title":{"rendered":"Impact de l'am\u00e9lioration du traitement sur la charge de morbidit\u00e9 de l'h\u00e9patite C chronique en Nouvelle-Z\u00e9lande"},"content":{"rendered":"

R\u00e9sum\u00e9<\/h2>\n\n\n\n

Arri\u00e8re-plan<\/h3>\n\n\n\n

L'h\u00e9patite C chronique est une cause importante d'insuffisance h\u00e9patique, de cancer du foie et de d\u00e9c\u00e8s li\u00e9s au foie en Nouvelle-Z\u00e9lande. Bien que ces complications puissent \u00eatre \u00e9vit\u00e9es par l'\u00e9radication du VHC, le recours actuel au traitement est <1% par an. Nous d\u00e9crivons le fardeau de l'infection par le VHC et estimons l'effet de quatre strat\u00e9gies de traitement diff\u00e9rentes pour r\u00e9duire la morbidit\u00e9 et la mortalit\u00e9 li\u00e9es au VHC.<\/p>\n\n\n\n

M\u00e9thodes<\/h3>\n\n\n\n

Les param\u00e8tres du mod\u00e8le de base \u00e9taient bas\u00e9s sur une revue de la litt\u00e9rature et un consensus d'experts, en se concentrant sur les donn\u00e9es n\u00e9o-z\u00e9landaises. Quatre sc\u00e9narios ont \u00e9t\u00e9 mod\u00e9lis\u00e9s: le sc\u00e9nario 1 a estim\u00e9 l'impact d'une efficacit\u00e9 accrue du traitement, tandis que le sc\u00e9nario 2 a estim\u00e9 l'effet d'une efficacit\u00e9 accrue du traitement et d'une augmentation progressive du nombre de patients trait\u00e9s. Les sc\u00e9narios 3 et 4 ont estim\u00e9 l'impact de l'introduction diff\u00e9r\u00e9e de nouveaux AAD pendant 1 ou 2 ans.<\/p>\n\n\n\n

R\u00e9sultats<\/h3>\n\n\n\n

La pr\u00e9valence de l'infection par le VHC a atteint un sommet en 2010 (50 480 cas). La pr\u00e9valence maximale de la cirrhose et du CHC se produira apr\u00e8s 2030. Le sc\u00e9nario 2 a entra\u00een\u00e9 une diminution sensible de la morbidit\u00e9 et de la mortalit\u00e9 li\u00e9es au VHC. L'impact du sc\u00e9nario 1 \u00e9tait moindre. Le report du financement des nouveaux traitements AAD pendant 1 ou 2 ans suppl\u00e9mentaires a entra\u00een\u00e9 une augmentation de 18-36% des d\u00e9c\u00e8s li\u00e9s au foie en 2030.<\/p>\n\n\n\n

Conclusions<\/h3>\n\n\n\n

Bien que la pr\u00e9valence de l'infection chronique par le VHC ait atteint un sommet, le fardeau de la maladie continue de cro\u00eetre. Une utilisation et une efficacit\u00e9 accrues du traitement, associ\u00e9es aux efforts visant \u00e0 r\u00e9duire la transmission de la maladie, aideront \u00e0 pr\u00e9venir les maladies h\u00e9patiques avanc\u00e9es et les d\u00e9c\u00e8s.<\/p>\n\n\n\n

Des pays:<\/strong> Nouvelle-Z\u00e9lande<\/p>\n\n

\n
Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Summary Background Chronic hepatitis C is an important cause of liver failure, liver cancer and liver-related deaths in New Zealand. Although these complications can be prevented by HCV eradication, current treatment uptake is <1% per annum. We describe the burden of HCV infection and estimate the effect of four different treatment strategies to reduce HCV-related […]<\/p>\n","protected":false},"author":24,"featured_media":3349,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10],"publication-author":[2177,535,1061,2140,2163,494,2120],"class_list":["post-2666","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","publication-author-brunton-c","publication-author-estes-c","publication-author-gane-e","publication-author-henderson-c","publication-author-radke-s","publication-author-razavi-h","publication-author-stedman-c"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2666"}],"version-history":[{"count":6,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2666\/revisions"}],"predecessor-version":[{"id":7617,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2666\/revisions\/7617"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3349"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2666"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}